The partnership brings together Salipro’s tech for stabilising drug targets from Boehringer’s drug discovery programmes.

Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched ...

Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s ...

The new initiative aims to improve early detection by increasing access to screening in communities where accessing care is ...

The One Medicine Platform replaces 20+ legacy platforms—unifying medicinal development processes & data sources into a ...

Salipro Biotech has signed a research and license agreement with Boehringer Ingelheim to accelerate the development of ...

Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate ...

Germany’s Boehringer Ingelheim has launched the One Medicine Platform, a new system designed to streamline drug development, ...

Cognizant (Nasdaq: CTSH) and Boehringer Ingelheim announced today the go-live of an end-to-end technology platform powered by ...

Boehringer Ingelheim and Veeva Systems have announced the launch of Boehringer’s One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They ...